Cognition comes of age: comments on the new FDA draft guidance for early Alzheimer’s disease

Abstract Background The FDA have recently published draft guidance for the development of treatments for early Alzheimer’s disease. Key features of this guidance are the advocacy of sensitive cognitive measures and a taxonomy of disease severity. Whilst desirable patterns of cognitive-functional imp...

Full description

Bibliographic Details
Main Author: John E. Harrison
Format: Article
Language:English
Published: BMC 2018-06-01
Series:Alzheimer’s Research & Therapy
Subjects:
Online Access:http://link.springer.com/article/10.1186/s13195-018-0386-7
id doaj-0aee91ff79124ed0b76576cf1fca72a6
record_format Article
spelling doaj-0aee91ff79124ed0b76576cf1fca72a62020-11-25T00:31:01ZengBMCAlzheimer’s Research & Therapy1758-91932018-06-011011610.1186/s13195-018-0386-7Cognition comes of age: comments on the new FDA draft guidance for early Alzheimer’s diseaseJohn E. Harrison0Metis Cognition Ltd.Abstract Background The FDA have recently published draft guidance for the development of treatments for early Alzheimer’s disease. Key features of this guidance are the advocacy of sensitive cognitive measures and a taxonomy of disease severity. Whilst desirable patterns of cognitive-functional improvement are included, specific measures, and the magnitude of required effects, are not described. Main section We describe key elements of the guidance content, especially with regard targeting key cognitive domains and the means by which they might be efficiently indexed in the disease stages included in the guidance. We discuss also the opportunities to assess cognitive performance in ‘Stage 2’ and ‘Stage 3’ patients, as well as the possibilities for effectively assessing function in the latter category. In this section we review candidate cognitive assessments that we judge are capable of delivering on the guidance specification for sensitive neuropsychological measures. This includes detailed consideration of the ADCS-PACC and Catch-Cog initiatives. With respect to the magnitude of effects, we propose that standardised effect sizes of 0.3 represent a reasonable level of efficacy based on the observation that already marketed drugs on average deliver this level of improvement. Conclusions We propose the use of cognitive measures in stage 2 patients to index the cognitive skills known to be compromised early in the Alzheimer’s disease process. We recommend extending the traditional interest in episodic memory to include sensitive, reliable and valid measures of attention, working memory and aspects of executive function. We propose a focus on these additional cognitive abilities based on evidence that performance on tests of these domains is moderately well related to functional skills.http://link.springer.com/article/10.1186/s13195-018-0386-7CognitionDementiaMemoryAttentionNeuropsychologicalAlzheimers
collection DOAJ
language English
format Article
sources DOAJ
author John E. Harrison
spellingShingle John E. Harrison
Cognition comes of age: comments on the new FDA draft guidance for early Alzheimer’s disease
Alzheimer’s Research & Therapy
Cognition
Dementia
Memory
Attention
Neuropsychological
Alzheimers
author_facet John E. Harrison
author_sort John E. Harrison
title Cognition comes of age: comments on the new FDA draft guidance for early Alzheimer’s disease
title_short Cognition comes of age: comments on the new FDA draft guidance for early Alzheimer’s disease
title_full Cognition comes of age: comments on the new FDA draft guidance for early Alzheimer’s disease
title_fullStr Cognition comes of age: comments on the new FDA draft guidance for early Alzheimer’s disease
title_full_unstemmed Cognition comes of age: comments on the new FDA draft guidance for early Alzheimer’s disease
title_sort cognition comes of age: comments on the new fda draft guidance for early alzheimer’s disease
publisher BMC
series Alzheimer’s Research & Therapy
issn 1758-9193
publishDate 2018-06-01
description Abstract Background The FDA have recently published draft guidance for the development of treatments for early Alzheimer’s disease. Key features of this guidance are the advocacy of sensitive cognitive measures and a taxonomy of disease severity. Whilst desirable patterns of cognitive-functional improvement are included, specific measures, and the magnitude of required effects, are not described. Main section We describe key elements of the guidance content, especially with regard targeting key cognitive domains and the means by which they might be efficiently indexed in the disease stages included in the guidance. We discuss also the opportunities to assess cognitive performance in ‘Stage 2’ and ‘Stage 3’ patients, as well as the possibilities for effectively assessing function in the latter category. In this section we review candidate cognitive assessments that we judge are capable of delivering on the guidance specification for sensitive neuropsychological measures. This includes detailed consideration of the ADCS-PACC and Catch-Cog initiatives. With respect to the magnitude of effects, we propose that standardised effect sizes of 0.3 represent a reasonable level of efficacy based on the observation that already marketed drugs on average deliver this level of improvement. Conclusions We propose the use of cognitive measures in stage 2 patients to index the cognitive skills known to be compromised early in the Alzheimer’s disease process. We recommend extending the traditional interest in episodic memory to include sensitive, reliable and valid measures of attention, working memory and aspects of executive function. We propose a focus on these additional cognitive abilities based on evidence that performance on tests of these domains is moderately well related to functional skills.
topic Cognition
Dementia
Memory
Attention
Neuropsychological
Alzheimers
url http://link.springer.com/article/10.1186/s13195-018-0386-7
work_keys_str_mv AT johneharrison cognitioncomesofagecommentsonthenewfdadraftguidanceforearlyalzheimersdisease
_version_ 1725324280168710144